Effect of opioid dependence pharmacotherapies on zidovudine disposition

Am J Addict. Fall 2001;10(4):296-307.

Abstract

Injection drug users are frequently infected with human immunodeficiency virus (HIV) and receive opioid dependence pharmacotherapies and zidovudine (ZDV), the latter as a component of highly active antiretroviral therapy. We previously reported that methadone substantially increases ZDV concentrations. We now report on oral ZDV pharmacokinetics in 52 subjects receiving the opioid dependence pharmacotherapies l-alpha-acetylmethadol LAAM, buprenorphine, or naltrexone, and 17 non-opioid-treated controls. Relative to the area under the time-concentration curve (AUC) of ZDV in control subjects, no statistically significant differences in ZDV AUC were observed in participants treated with LAAM (p = .75), buprenorphine (p = .37), or naltrexone (p = .34). While methadone maintenance may result in ZDV toxicity and possibly require dose adjustments, other opioid pharmacotherapies should not produce ZDV toxicity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / blood
  • Anti-HIV Agents / pharmacokinetics*
  • Anti-HIV Agents / therapeutic use
  • Buprenorphine / therapeutic use
  • Drug Interactions
  • Female
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Methadyl Acetate / therapeutic use
  • Naltrexone / therapeutic use
  • Narcotic Antagonists / therapeutic use
  • Narcotics / therapeutic use
  • Opioid-Related Disorders / drug therapy*
  • Radioimmunoassay
  • Substance Abuse Detection
  • Time Factors
  • Zidovudine / blood
  • Zidovudine / pharmacokinetics*
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • Narcotic Antagonists
  • Narcotics
  • Buprenorphine
  • Zidovudine
  • Naltrexone
  • Methadyl Acetate